Physician profile
Coreyann Fluker
NPI 1467965236
$20,169.95
in general payments reported to CMS, 2019-2025
49 companies · $4,129 in 2025
The $4,129 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,981 · 2022: $3,110 · 2023: $4,852 · 2024: $4,097 · 2025: $4,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $71.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,007.11 |
| Education | $71.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,011.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,390.49 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $1,669.56 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Alkermes, INC. | $1,575.34 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,264.16 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,192.55 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $794.37 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $720.71 | 2021-2025 | Trintellix |
| Lundbeck LLC | $705.29 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $699.21 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $675.43 | 2021-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.80 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $540.71 | 2023-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $520.93 | 2021-2025 | Farxiga, Fasenra, Bevespi Aerosphere |
| Corium, LLC | $496.82 | 2023-2025 | Azstarys |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $402.49 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Abbott Laboratories | $399.35 | 2021-2025 | Freestyle Libre 3, Proclaim, Amplatzer Amulet |
| Almatica Pharma LLC | $243.78 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $238.51 | 2022-2025 | Quviviq, Quviviq |
| Pfizer INC. | $226.84 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.64 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $195.81 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $162.60 | 2023-2025 | Cobenfy, Eliquis |
| Cequr Corporation | $125.75 | 2023-2024 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $119.61 | 2022-2025 | |
| Astellas Pharma US INC | $110.24 | 2022-2024 | Myrbetriq, Veozah |
| Glaxosmithkline, LLC. | $109.38 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Jazz Pharmaceuticals INC. | $95.19 | 2021 | |
| Exact Sciences Corporation | $89.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Collegium Pharmaceutical, INC. | $78.60 | 2025 | Jornay Pm |
| Indivior INC. | $63.22 | 2022-2023 | Sublocade |
| Eisai INC. | $49.00 | 2021-2022 | |
| Abiomed | $38.31 | 2024 | Impella |
| Ironshore Pharmaceuticals INC. | $38.08 | 2023-2024 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $38.04 | 2021-2023 | Gvoke Hypopen |
| Medtronic, INC. | $37.95 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.71 | 2021-2024 | Trulance, Xifaxan |
| Adlon Therapeutics L.P. | $24.98 | 2021 | |
| Tonix Medicines, INC. | $24.68 | 2025 | Tonmya |
| Organon LLC | $21.56 | 2021 | |
| Phadia US INC. | $21.15 | 2024 | Immunocap |
| Sage Therapeutics, LLC | $20.94 | 2025 | Zurzuvae |
| Axonics, INC. | $15.15 | 2023 | Axonics |
| Sanofi-Aventis U.S. LLC | $14.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.37 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.24 | 2025 | |
| Merck Sharp & Dohme LLC | $13.47 | 2023 | Belsomra |
| Currax Pharmaceuticals LLC | $13.28 | 2022 | |
| Sanofi Pasteur INC. | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coreyann Fluker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.